NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as ACCORD. It is marketed under 1 brand name, including CAMCEVI KIT. Available in 1 different strength, such as EQ 42MG BASE, and administered through 1 route including EMULSION;SUBCUTANEOUS.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"56137","ingredient":"LEUPROLIDE MESYLATE","trade_name":"CAMCEVI KIT","family_id":"ebeca351ccc9446ea79a","publication_number":"US10646572B2","cleaned_patent_number":"10646572","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-01-16","publication_date":"2020-05-12","legal_status":"Granted"} | US10646572B2 Formulation | 12 May, 2020 | Granted | 16 Jan, 2027 | |
| {"application_id":"56153","ingredient":"LEUPROLIDE MESYLATE","trade_name":"CAMCEVI KIT","family_id":"ebeca351ccc9446ea79a","publication_number":"US9572857B2","cleaned_patent_number":"9572857","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-01-16","publication_date":"2017-02-21","legal_status":"Granted"} | US9572857B2 Formulation | 21 Feb, 2017 | Granted | 16 Jan, 2027 | |
| {"application_id":"56154","ingredient":"LEUPROLIDE MESYLATE","trade_name":"CAMCEVI KIT","family_id":"ebeca351ccc9446ea79a","publication_number":"US9744207B2","cleaned_patent_number":"9744207","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-01-16","publication_date":"2017-08-29","legal_status":"Granted"} | US9744207B2 Formulation | 29 Aug, 2017 | Granted | 16 Jan, 2027 | |
| {"application_id":"138448","ingredient":"LEUPROLIDE MESYLATE","trade_name":"CAMCEVI KIT","family_id":"","publication_number":"","cleaned_patent_number":"12133878","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-12-18","publication_date":"2024-11-05","legal_status":"Patented Case"} | US12133878B2 Formulation | 05 Nov, 2024 | Patented Case | 18 Dec, 2037 | |
| {"application_id":"115004","ingredient":"LEUPROLIDE MESYLATE","trade_name":"CAMCEVI KIT","family_id":"61349323b8b744b481ac","publication_number":"US11717555B2","cleaned_patent_number":"11717555","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-01-01","publication_date":"2023-08-08","legal_status":"Granted"} | US11717555B2 Formulation | 08 Aug, 2023 | Granted | 01 Jan, 2039 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Leuprolide Mesylate
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.